Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification

Christin Krause, Helen Sievert, Cathleen Geißler, Martina Grohs, Alexander T. El Gammal, Stefan Wolter, Olena Ohlei, Fabian Kilpert, Ulrike M. Krämer, Meike Kasten, Christine Klein, Georg E. Brabant, Oliver Mann, Hendrik Lehnert, Henriette Kirchner*

*Corresponding author for this work


Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.

Original languageEnglish
Issue number8
Pages (from-to)885-897
Number of pages13
Publication statusPublished - 01.06.2019


Dive into the research topics of 'Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification'. Together they form a unique fingerprint.

Cite this